678 related articles for article (PubMed ID: 28838196)
21. Poliovirus vaccines. Progress toward global poliomyelitis eradication and changing routine immunization recommendations in the United States.
Sutter RW; Prevots DR; Cochi SL
Pediatr Clin North Am; 2000 Apr; 47(2):287-308. PubMed ID: 10761505
[TBL] [Abstract][Full Text] [Related]
22. Health economic analysis of vaccine options for the polio eradication endgame: 2022-2036.
Thompson KM; Kalkowska DA; Badizadegan K
Expert Rev Vaccines; 2022 Nov; 21(11):1667-1674. PubMed ID: 36154436
[TBL] [Abstract][Full Text] [Related]
23. Strengthening the partnership between routine immunization and the global polio eradication initiative to achieve eradication and assure sustainability.
Abdelwahab J; Dietz V; Eggers R; Maher C; Olaniran M; Sandhu H; Vandelaer J
J Infect Dis; 2014 Nov; 210 Suppl 1(Suppl 1):S498-503. PubMed ID: 25316872
[TBL] [Abstract][Full Text] [Related]
24. The Need and Potential of Inactivated Poliovirus Vaccine.
Garon J; Orenstein W; John TJ
Indian Pediatr; 2016 Aug; 53 Suppl 1():S2-S6. PubMed ID: 27771632
[TBL] [Abstract][Full Text] [Related]
25. Polio Endgame, Information Gaps Related to Vaccines and Immunity.
Ahmad M; Bahl S; Kunwar A
Indian Pediatr; 2016 Aug; 53 Suppl 1():S33-S37. PubMed ID: 27771637
[TBL] [Abstract][Full Text] [Related]
26. Introduction of Inactivated Poliovirus Vaccine and Trivalent Oral Polio Vaccine/Bivalent Oral Polio Vaccine Switch in the African Region.
Tevi-Benissan C; Okeibunor J; du Châtellier GM; Assefa A; Biey JN; Cheikh D; Eshetu M; Anya BP; Dao H; Nasir Y; Akanmori BD; Mihigo R
J Infect Dis; 2017 Jul; 216(suppl_1):S66-S75. PubMed ID: 28838178
[TBL] [Abstract][Full Text] [Related]
27. Anti-polio vaccinations in the third millennia.
Icardi G; Tassinari F
Ann Ig; 2018; 30(4 Supple 1):11-15. PubMed ID: 30062374
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity of New Primary Immunization Schedules With Inactivated Poliovirus Vaccine and Bivalent Oral Polio Vaccine for the Polio Endgame: A Review.
Bandyopadhyay AS; Modlin JF; Wenger J; Gast C
Clin Infect Dis; 2018 Oct; 67(suppl_1):S35-S41. PubMed ID: 30376081
[TBL] [Abstract][Full Text] [Related]
29. Immunization Against Poliomyelitis and the Challenges to Worldwide Poliomyelitis Eradication.
Modlin JF; Bandyopadhyay AS; Sutter R
J Infect Dis; 2021 Sep; 224(12 Suppl 2):S398-S404. PubMed ID: 34590135
[TBL] [Abstract][Full Text] [Related]
30. Experience With Inactivated Polio Vaccine Introduction and the "Switch" From Trivalent to Bivalent Oral Polio Vaccine in the World Health Organization's Western Pacific Region.
Gurung S; Harris JB; Eltayeb AO; Hampton LM; Diorditsa S; Avagyan T; Schluter WW
J Infect Dis; 2017 Jul; 216(suppl_1):S101-S108. PubMed ID: 28838170
[TBL] [Abstract][Full Text] [Related]
31. Expected Implications of Globally Coordinated Cessation of Serotype 3 Oral Poliovirus Vaccine (OPV) Before Serotype 1 OPV.
Kalkowska DA; Thompson KM
Risk Anal; 2021 Feb; 41(2):312-319. PubMed ID: 32936466
[TBL] [Abstract][Full Text] [Related]
32. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016.
Hampton LM; Farrell M; Ramirez-Gonzalez A; Menning L; Shendale S; Lewis I; Rubin J; Garon J; Harris J; Hyde T; Wassilak S; Patel M; Nandy R; Chang-Blanc D;
MMWR Morb Mortal Wkly Rep; 2016 Sep; 65(35):934-8. PubMed ID: 27606675
[TBL] [Abstract][Full Text] [Related]
33. Introduction of Inactivated Poliovirus Vaccine and Impact on Vaccine-Associated Paralytic Poliomyelitis - Beijing, China, 2014-2016.
Zhao D; Ma R; Zhou T; Yang F; Wu J; Sun H; Liu F; Lu L; Li X; Zuo S; Yao W; Yin J
MMWR Morb Mortal Wkly Rep; 2017 Dec; 66(49):1357-1361. PubMed ID: 29240729
[TBL] [Abstract][Full Text] [Related]
34. Coverage estimates and patterns of inactivated poliovirus vaccine (IPV) use prior to and during the polio eradication endgame, Jinan City, China, 2010-2015.
Chang C; Zhang J; Zhou J; Cao R; Song K; Liu C; Zhang X; Geng X; Liu X; Li C
Hum Vaccin Immunother; 2016 Nov; 12(11):2749-2752. PubMed ID: 27437792
[TBL] [Abstract][Full Text] [Related]
35. [Polio vaccines, eradication and posterradication].
Salmerón García F; Portela Moreira A; Soler Soneira M; López Hernández S; Chamorro Somoza Díaz-Sarmiento M; Pérez González I; Rubio Gómez MI; Pérez González A; Sagredo Rodríguez A; Ruiz Antúnez S; Timón Jiménez M; Frutos Cabanillas G
Rev Esp Salud Publica; 2013; 87(5):497-505. PubMed ID: 24322286
[TBL] [Abstract][Full Text] [Related]
36. A new challenge for the world: the eradication of polio.
Gentile Á; Abate H
Arch Argent Pediatr; 2016 Dec; 114(6):557-562. PubMed ID: 27869415
[TBL] [Abstract][Full Text] [Related]
37. Polio eradication in the African Region on course despite public health emergencies.
Okeibunor JC; Ota MC; Akanmori BD; Gumede N; Shaba K; Kouadio KI; Poy A; Mihigo R; Salla M; Moeti MR
Vaccine; 2017 Mar; 35(9):1202-1206. PubMed ID: 26303876
[TBL] [Abstract][Full Text] [Related]
38. A Supply and Demand Management Perspective on the Accelerated Global Introductions of Inactivated Poliovirus Vaccine in a Constrained Supply Market.
Lewis I; Ottosen A; Rubin J; Blanc DC; Zipursky S; Wootton E
J Infect Dis; 2017 Jul; 216(suppl_1):S33-S39. PubMed ID: 28838159
[TBL] [Abstract][Full Text] [Related]
39. India's Preparedness for Introduction of IPV and Switch from tOPV to bOPV.
Haldar P; Agrawal P
Indian Pediatr; 2016 Aug; 53 Suppl 1():S44-S49. PubMed ID: 27771639
[TBL] [Abstract][Full Text] [Related]
40. Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame.
Parker EP; Molodecky NA; Pons-Salort M; O'Reilly KM; Grassly NC
Expert Rev Vaccines; 2015; 14(8):1113-23. PubMed ID: 26159938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
